Our proprietary Pdx-NPTM is innovative silica-based drug delivery technology that can load multiple cargo types at once (e.g., oligonucleotides, adjuvants, antibodies, chemotherapeutics, proteins) with superior outcomes than the free drug counterparts, creating a myriad of new intellectual properties. It can target both cancer and immune cells, generating cancer specific immune response. To date, we have over 35 patent applications pending examination and 5 US patents issued, encompassing compositions and methods of use for our nanoparticle platform and novel combination therapeutics
Our first two candidates, ARAC-02 and AIRISE-02, utilize patients’ own tumors to create cancer specific immune response (CD8+ T cells). They bypass the need to identify tumor antigens or engineer T cells outside the body (e.g., CAR T cells). They can kill cancer cells and generate a tumor specific T cell response while modulating the immunosuppressive tumor environment.
ARAC-02 development achieved the perfect score during SBIR grant review, and won $2.3M award from the NCI in 2021. Data on its first-gen ARAC was published in Nature Communications in 2022.
AIRISE-02 has been published in Advanced Materials and won $2.0M award from the National Cancer Institute (NCI) in 2021.